SELLAS Life Sciences shares fell sharply without any disclosed failed clinical event in the public record, highlighting the market’s sensitivity to timing around binary readouts. The company’s stock dropped 14.4% after a day with no new filings or company news explaining the move, despite the company being two events from completion of its Phase 3 REGAL trial. SELLAS said in August it would announce the 80th event for galinpepimut-S maintenance therapy in AML patients in second complete remission, but one month later the expected trigger was not reflected in issuers’ filings or news. REGAL remains blinded, leaving the market to interpret timing rather than results. The episode reinforces how investor expectations can shift when study event timing extends or slips—especially in pre-topline periods when companies are still progressing their second program, SLS009 (tambiciclib), in newly diagnosed AML.